Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid

Dear Editor,

Bullous Pemphigoid (BP) is a serious cutaneous autoimmune disease with distinctly associated comorbidities such as neurological disorders, hypertension, and diabetes mellitus. Recently, the use of Dipeptidyl Peptidase-4 Inhibitors/gliptins (DPP4i) to control hyperglycemia was linked to the increasing prevalence of Type 2 Diabetes Mellitus (T2DM) among patients with newly diagnosed BP, demonstrating that the association of different drugs to certain comorbidities might partly account for the observed link of some comorbidities to BP. Accordingly, we asked whether medications used to treat further comorbidities might have modified the risk to develop BP in this setting. Herein, we report our findings on the association of BP with non-antidiabetic medications used at the time of BP diagnosis in a single-center cohort of elderly (≥70 years old) DPP4i-treated T2DM patients.

The BP cohort consisted of 45 T2DM patients on DPP4i with newly diagnosed BP after January 2010. BP diagnostic criteria were displayed in Table 1. All BP patients in this cohort were treated uniformly according to institutional guidelines with discontinuation of DPP4i and the combination of systemic corticosteroids in tapered doses and methotrexate used as corticosteroid-sparing agent. The controls were 98 elderly T2DM patients without BP treated with DPP4i for at least the last 30 months prior to enrollment matched at a ratio of 1:2 on gender, age (within 2 years), and year of diagnosis. Employing SPSS, categorical variables were compared with the χ² test, and Mantel-Haenszel and Cox proportional hazard odds ratios (OR ± 95% Confidence Intervals, CI) were calculated between patients with and without BP at p-level <0.05. The findings are part of a retrospective study approved by the Institutional Research and Ethics Committee.

The spectrum of the employed DPP4i did not differ between patients with and without BP (p = 0.06). Core demographic and medical history data of BP patients and controls are summarized in Table 2. Drug groups were included in the analysis when at least 10/143 patients were on regular treatment using medications of each group. Evaluating these groups together, a significantly higher risk of BP was found for patients on anticoagulants, proton pump inhibitors, and selective serotonin reuptake inhibitors, whereas the BP risk was significantly lower for those T2DM patients on statins (Table 3). Furthermore, the link of statin intake with a reduced BP risk was the only association that remained significant after focusing the analysis on the four drug groups above (Cox HR = 0.165; CI = 0.038–0.723; p = 0.017). The main limitation of this study is the relatively small number of participants; however, the cohorts were reasonably homogeneous with a noticeable number of BP patients included.

Statin intake might lower the risk of developing BP in patients with T2DM treated with DPP4i by modifying certain inflammatory processes, probably via the promotion of an anti-inflammatory shift by inhibiting Th17 cells and IL-17 production. For example, in an animal model of allergic asthma, simvastatin modified the influx of inflammatory cells, including eosinophils and Treg, into the target tissues.

Recently, Guo et al. reported a significantly increased association of the use of spironolactone with the risk of developing BP among patients taking DPP4i, even after adjustment for confounders (HR = 5.50, 95% CI = 1.25–7.51). Notably, although we did not evaluate specifically the effect of spironolactone, we could not confirm a higher BP risk for patients taking any K-sparing diuretic (Table 3). It is possible that variation of genetic factors in remote populations (like Korean vs. Greek patients), including differences in BP susceptibility and/or diverging pharmacogenomics, may explain differences in the susceptibility of the association of certain drugs to BP development.

It has been suggested that DPP4i-induced BP may become a model disease for a better understanding of basic autoimmunity principles. Targeting the role of co-medications in triggering BP in DPP4i-treated T2DM patients in prospective studies with sufficiently large patient samples might provide essential contributions to delineate missing links in the pathogenesis of this disease.

Financial support

None declared.

Authors’ contributions

Agoritsa Gravani and Ioannis Bassukas designed the study.

Agoritsa Gravani, Panagiota Christou and Stelios Tigas collected data. All authors contributed to data analysis.

Agoritsa Gravani was responsible for the 1st draft; all authors revised critically and approved the final version of the manuscript.

---

Table 1 Criteria for the diagnosis of Bullous Pemphigoid (BP).

| All 3 criteria must be fulfilled: |
|----------------------------------|
| (a) Relevant clinical presentation |
| (b) Lesional skin biopsy consistent with BP |
| (c) A result consistent with the diagnosis BP in at least one of the following routinely available laboratory examinations: direct immunofluorescence, indirect immunofluorescence, or ELISA |

---

1. How to cite this article: Gravani A, Christou P, Tigas S, Bassukas ID. Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid. An Bras Dermatol. 2021;96:782-4.

2. Study conducted at the University Hospital of Ioannina, Ioannina, Greece.
Table 2  Core demographic characteristics and disease history data of n = 45 bullous pemphigoid patients (BP) and n = 98 controls.

| Attribute                                           | BP, n (%)          | Control, n (%)        |
|-----------------------------------------------------|--------------------|-----------------------|
| Male gender                                         | n = 19 (42.2%)     | n = 41 (41.8%)        |
| Female gender                                       | n = 26 (57.8%)     | n = 57 (58.2%)        |
| Age (years); Median [Range]:                        | 80 (70–92)         | 76.5 (70–90)          |
| DPP4 use interval (months) – Median [Range]         | 16 (0.3–60)        | 43.5 (30–125)         |
| Mean                                                | 19.6               | 53.9                  |

**Comorbidities**

| Cardiovascular                                      | n = 40 (88.9%)     | n = 88 (89.8%)        |
| Pulmonary                                           | n = 6 (13.3%)      | n = 7 (7.1%)          |
| Malignancies, excluding hematologic                 | n = 1 (2%)         | n = 0 (0%)            |
| Psychiatric                                         | n = 9 (20%)        | n = 10 (10.2%)        |
| Neurologic                                          | n = 7 (15.5%)      | n = 6 (6.1%)          |
| Gastrointestinal                                    | n = 11 (24.4%)     | n = 15 (15.3%)        |
| Metabolic (dyslipidemia, hyperuricemia)             | n = 29 (64.4%)     | n = 72 (73.5%)        |
| Urogenital                                          | n = 7 (15.6%)      | n = 7 (7.1%)          |
| Hematologic diseases, including malignancies        | n = 5 (11.1%)      | n = 0 (0%)            |
| Ear Nose Throat / Eye disorders                     | n = 4 (8.9%)       | n = 0 (0%)            |
| Rheumatologic                                       | n = 2 (4.4%)       | n = 4 (4.1%)          |
| Cutaneous                                           | n = 3 (6.7%)       | n = 0 (0%)            |
| Endocrine other than diabetes mellitus              | n = 4 (8.7%)       | n = 10 (10.2%)        |

Table 3  Medications in patients with DPP4i associated bullous pemphigoid and in patients without BP despite DPP4i use.

| Medication                                      | Cohort, n (%)          | p        | OR<sup>a</sup> | CI<sup>b</sup> for OR |
|-------------------------------------------------|------------------------|----------|----------------|-----------------------|
| Anticoagulants                                  | 24 (53.3%)             | 34 (34.7%) | 0.026 | 2.300 | 1.104 | 4.793 |
| a1-adrenergic inhibitors                        | 6 (13.3%)              | 7 (7.1%)  | 0.220 | 2.062 | 0.649 | 6.550 |
| ACE/AT2 inhibitors<sup>c</sup>                  | 36 (80%)               | 63 (64.3%) | 0.064 | 2.292 | 0.954 | 5.503 |
| Beta-blockers                                   | 18 (40%)               | 33 (33.7%) | 0.276 | 1.510 | 0.719 | 3.170 |
| Calcium channel blockers                       | 14 (31.1%)             | 41 (41.8%) | 0.165 | 0.581 | 0.270 | 1.252 |
| Loop diuretics                                  | 11 (24.4%)             | 21 (21.4%) | 0.444 | 1.393 | 0.596 | 3.170 |
| Thiazide diuretics                              | 20 (44.4%)             | 29 (29.6%) | 0.065 | 2.009 | 0.958 | 4.214 |
| Potassium sparing diuretics                     | 5 (11.1%)              | 5 (5.1%)  | 0.113 | 3.026 | 0.771 | 11.886 |
| Centrally acting antihypertensive drugs         | 4 (8%)                 | 6 (6.1%)  | 0.522 | 1.538 | 0.411 | 5.785 |
| Statins                                         | 21 (46.7%)             | 67 (68.4%) | 0.010 | 0.376 | 0.179 | 0.790 |
| Hypolipidemic, other                            | 4 (8%)                 | 8 (8.2%)  | 0.851 | 1.128 | 0.321 | 3.970 |
| Thyroxine                                       | 3 (6.7%)               | 9 (9.2%)  | 0.643 | 0.725 | 0.186 | 2.823 |
| Proton pump inhibitors                          | 12 (26.7%)             | 8 (8.2%)  | 0.009 | 3.781 | 1.396 | 10.243 |
| Benzodiazepines                                 | 6 (13.3%)              | 4 (4.1%)  | 0.051 | 3.730 | 0.995 | 13.982 |
| Selective serotonin reuptake inhibitors         | 9 (20%)                | 6 (6.1%)  | 0.032 | 3.429 | 1.110 | 10.595 |

<sup>a</sup>  Mantel-Haenszel Odds Ratio.
<sup>b</sup>  CI, 95% Confidence Intervals.
<sup>c</sup>  Angiotensin Converting Enzyme inhibitors & Angiotensin II receptor blockers.

Conflicts of interest

None declared.

References

1. Gravani A, Gaitanis G, Tsironi T, Tigas S, Bassukas ID. Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors. J Eur Acad Dermatol Venereol. 2018;32:e438–9.

2. Egesi A, Sun G, Khachemoune A, Rashid RM. Statins in skin: research and rediscovery, from psoriasis to sclerosis. J Drugs Dermatol. 2010;9:921–7.

3. Jha A, Ryu MH, Oo O, Bews J, Carlson C, Scwartz J, et al. Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. Br J Pharmacol. 2018;175:1004–16.

4. Guo JY, Chen HH, Yang YC, Wu PY, Chang MP, Chen CC. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study. J Diabetes Complications. 2020;34:107515.
Efficacy of intermittent topical 5-fluorouracil 5% and oral nicotinamide in the skin field cancerization: a randomized clinical trial

Dear Editor,

Actinic keratosis (AK) is the fourth most commonly diagnosed dermatosis in Brazilian dermatology consultations and one of the most frequent diagnoses in patients over 65 years of age. The risk of malignancy of a single AK is low; however, multiple AKs in the same patient multiply the individual risk, which, added to the impossibility of determining which lesion will become malignant, makes the treatment and clinical follow-up of all AKs essential.

The presence of more than one AK in the same area clinically characterizes active skin field cancerization (SFC). Recently, SFC stabilization strategies have been studied, aiming at preventing the incidence of skin tumors, their recurrence, or the evolution of existing lesions.

5-Fluorouracil (5FU) is a topical chemotherapeutic agent with excellent response, reducing AK counts up to 80%, and stabilizing SFC. However, side effects caused by its daily use can lead to poor adherence and a poor outcome. Despite the description of several therapeutic regimens, its intermittent use for SFC stabilization has not been adequately tested.

Nicotinamide is a B-complex vitamin that works on DNA repair, reducing the effects of skin immunosuppression caused by ultraviolet radiation (UVR), modulating the production of inflammatory cytokines, and restoring cell energy levels after exposure to UVR. Moreover, oral nicotinamide seems to have a photoprotective effect in humans, reducing AK count and the incidence of skin neoplasms in high-risk patients.

An open, randomized, comparative, factorial, self-controlled, double-blind (for nicotinamide) clinical trial was carried out, in which 36 patients whose forearms had three to ten AKs each, were randomized into two groups. One group received 500 mg of oral nicotinamide every 12 hours for 120 days and the other group received a placebo at the same dose. Their forearms were subsequently randomized to receive topical 5FU in the evening, three times a week, or sunscreen with a sun protection factor (SPF) of 30 three times a day. The patients were clinically evaluated for AK counts in a standardized area of the forearms, and the forearm photoaging scale (FPS), which assesses the forearms regarding photoaging aspects, such as wrinkles, melanosomes, visible purpura, elastosis, and stellar scars, associated with the presence of AKs.

Additionally, patients were submitted to a biopsy in the central region of the forearm, in the skin without clinically evident AKs, to evaluate epithelial dysplasia based on KIN (Keratinocyte Intraepithelial Neoplasia) and immunohistochemical analysis of p53 and Ki67 markers, at enrollment and after 120 days. The primary outcome was complete clearance of AK and the secondary ones were partial clearance (> 50%) and reduced FPS, KIN and p53, and Ki67 expression.

The analysis unit of this study was each forearm. The results were analyzed by intention to treat, and dropouts were imputed using the mixed model. Variables were compared according to time and the groups using a (multilevel) linear mixed-effects model with a robust covariance matrix. The post-hoc analysis was performed using Sidak’s sequential procedure. Statistical significance was set at p < 0.05.

The patients’ demographic data are shown in Table 1. Of the 36 analyzed patients, three were dropouts: one due to death (unrelated to the study interventions), one due to improvement in the lesions, and one due to an adverse effect of the 5FU.

Table 2 shows the main clinical and histopathological results of the study. Improvement in AK count and photoaging scale were greater with 5FU when compared to sunscreen use, with no difference between groups in terms

How to cite this article: Ferreira ER, Miola AC, Lima TRR, Schmitt Jv, Abbade LFP, Miot HA. Efficacy of intermittent topical 5-fluorouracil 5% and oral nicotinamide in the skin field cancerization: a randomized clinical trial. An Bras Dermatol. 2021;96:784–7.

Study conducted at the Dermatology Outpatient Clinic, Faculty of Medicine, Universidade Estadual Paulista, São Paulo, SP, Brazil.